Request Sample
Request Methodology
Description
The Global Immunohistochemistry Market was valued US$ 2.2 Bn in the year 2020 and is anticipated to grow at US$ 3.58 Bn till 2027 witnessing a CAGR of 7.2% over the forecast period 2021-2027. Due to the increase in the geriatric population rising prevalence of chronic disease conditions such as Cancer, Auto-immune diseases, Diabetes, Infections & Others and rising technological advancement of in-vitro diagnostics boosts the growth of the immunohistochemistry market. However, high cost of immunohistochemistry test, lack of trained professional to perform the immunohistochemistry test and the concerns related with accuracy of the diagnostic results are the major factors that hinder the growth of the immunohistochemistry market. Global market report gives comprehensive outlook on immunohistochemistry across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report on global immunohistochemistry market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application, end user and region. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global immunohistochemistry market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities). Key stakeholders of the global immunohistochemistry market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global immunohistochemistry products. Global market is surging owing to frequent acquisitions and launchings by the market players. In June 2018, Agilent Technologies Inc. launched a new diagnostic kit which enabled Dako Omnis system of company to analyse tissue sample by using three different techniques (immunohistochemical (IHC), fluorescence in situ hybridization (FISH) assays and chromogenic in situ hybridization (CISH)) assays at a time at the same time. This new technology would help in reducing the time and support better healthcare case.
